Homozygous Familial Hypercholesterolemia
ARWRArrowhead PharmaceuticalsCatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Zodasiran (ARO-ANG3) in Homozygous Familial Hypercholesterolemia. The expected timing is based on the latest available company guidance and may change.
YOSEMITE study. 7/8/25- Initiated Ph3 trial. 11/25/25:- First subject dosed in YOSEMITE Ph3 HoFH trial; no data timeline disclosed. 07/27/26:- YOSEMITE Ph3 enrollment complete. Study completion expected Mid-2027. FDA Orphan Drug Designation noted.
Verification
Confirm timing and program details against the company announcement or filing.